Two advances in the management of Parkinson disease.
Open Access
- 1 August 2002
- journal article
- review article
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 69 (8) , 639-643
- https://doi.org/10.3949/ccjm.69.8.639
Abstract
Levodopa should generally be avoided early in the course of Parkinson disease; dopamine agonists, particularly second-generation agents such as ropinirole (Requip) and pramipexole (Mirapex), carry a smaller long-term risk of dyskinesia and should be used instead. Deep brain stimulation is remarkably effective in refractory cases and may well usher in a new era in the treatment of chronic neurologic disease.Keywords
This publication has 0 references indexed in Scilit: